Bvf Inc Unicycive Therapeutics, Inc. Transaction History

Bvf Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.4 - $1.46 $564,640 - $2.06 Million	-1,411,601 Reduced 39.09%	2,200,000 $1.1 Million
Q1 2024 May 15, 2024	BUY	$0.83 - $1.79 $1.24 Million - $2.67 Million	1,493,462 Added 70.51%	3,611,601 $4.98 Million
Q4 2023 Feb 14, 2024	SELL	$0.49 - $0.92 $634,757 - $1.19 Million	-1,295,424 Reduced 37.95%	2,118,139 $1.84 Million
Q3 2023 Nov 14, 2023	BUY	$0.61 - $1.31 $2.08 Million - $4.47 Million	3,413,563 New	3,413,563 $2.94 Million

46.8M

Ticker UNCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,052,500
Market Cap $10.4M
Description
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

Stay updated on Bvf Inc with notifications on news.